NetworkNewsBreaks – CytoDyn Inc.’s (CYDY) PCaTest Clinical Study Results Demonstrate Added Value to Gleason Score, Further Support FDA filing
Biotechnology company CytoDyn (OTCQB: CYDY) today announced recent clinical study results showing that its PCaTest provides substantial additive value for predicting outcomes for prostate cancer patients compared to the Gleason score, the current standard for prostate cancer diagnosis. The new findings support CYDY’s strategy for seeking FDA approval for the PCaTest. “Unfortunately, current tests not able to precisely determine whether an individual’s cancer will result in death if not treated aggressively,” CytoDyn Chief Medical Officer and developer of the PCaTest Richard Pestell , M.D., Ph.D., F.A.C.P., M.B.A., stated in the news release. “On the other hand, aggressive treatment for prostate…







